We've put some small files called cookies on your device to make our site work.
We'd also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We'll use a cookie to save your choice. You can read more about our cookies before you choose.
Clinical Commissioning Policy: Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy
This document describes the evidence that has been considered by NHS England informulating a policy to routinely commission tolvaptan for hyponatraemia secondary to SIADH in patients requiring cancer chemotherapy.
